However, evidence from recent studies suggests that MCC carrying extended KRAS exon 2 mutations predicted for the lack of activity of anti-epidermal growth factor receptor (EGFR) therapies and resulted in restriction to the use of anti-EGFR monoclonal antibodies, making these drugs suitable for the so-called “super” wild-type patients only [7–9]. Here, KRAS is linked to Merkel cell skin cancer.